Autologous hematopoietic stem cell transplantation (ASCT) outcomes in non-Hodgkin lymphoma (NHL) patients undergoing high dose therapy (HDT) with etoposide, cyclophosphamide and thiotepa (VP/CY/TT) versus cyclophosphamide, carmustine and etoposide (CBV)

被引：0
|
作者：
Veltri, L. W. [1 ]
Shah, N. [1 ]
Cumpston, A. [1 ]
Zhang, J. [1 ]
Wen, S. [1 ]
Watkins, K. [1 ]
Leadmon, S. [1 ]
Craig, M. [1 ]
Hamadani, M. [2 ]
Kanate, A. S. [1 ]
机构：
[1] W Virginia Univ, Hematol Oncol, Morgantown, WV 26506 USA
[2] Med Coll Wisconsin, Hematol Oncol, Milwaukee, WI 53226 USA
来源：
BONE MARROW TRANSPLANTATION | 2016年 / 51卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P237
引用
收藏
页码：S238 / S238
页数：1
相关论文
共 50 条
  • [1] High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma
    Law, Lisa Y.
    Horning, Sandra J.
    Wong, Ruby M.
    Johnston, Laura J.
    Laport, Ginna G.
    Lowsky, Robert
    Shizuru, Judith A.
    Blume, Karl G.
    Negrin, Robert S.
    Stockerl-Goldstein, Keith E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (07) : 703 - 711
  • [2] Early transplant related mortality in lymphoma patients undergoing autologous hematopoietic stem cell transplantation after conditioning with CBV (cyclophosphamide, carmustine and etoposide)
    Regadera, A
    Jarque, I
    de la Rubia, J
    Andreu, R
    Garcia, I
    Moscardó, F
    Mena, A
    Yuste, A
    Jimenez, C
    Martín, G
    Martínez, J
    Sanz, G
    Saavedra, S
    Mollá, S
    Plumé, G
    Sanz, MA
    BONE MARROW TRANSPLANTATION, 2001, 27 : S264 - S264
  • [3] Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma
    Robertson, MJ
    Abonour, R
    Hromas, R
    Nelson, RP
    Fineberg, NS
    Cornetta, K
    LEUKEMIA & LYMPHOMA, 2005, 46 (10) : 1477 - 1487
  • [4] BUSULFAN, CYCLOPHOSPHAMIDE, ETOPOSIDE (BUCYVP) OR CARMUSTINE, ETOPOSIDE, CYTARABINE, MELPHELAN (BEAM) FOR CONDITIONING PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS WITH HODGKIN LYMPHOMA (HL)?
    Salem, G.
    Ruppert, A. S.
    Efebera, Y.
    Elder, P.
    Bingman, A.
    Penza, S.
    Andritsos, L. A.
    Devine, S. M.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S246 - S246
  • [5] BEAC (carmustine, etoposide, cytarabine, and cyclophosphamide) in autologous hematopoietic cell transplantation: a safe and effective alternative conditioning regimen for Hodgkin and non-Hodgkin lymphoma
    Sakellari, Ioanna
    Gavriilaki, Eleni
    Bouziana, Stella
    Constantinou, Varnavas
    Mallouri, Despina
    Vardi, Anna
    Marvaki, Anastasia
    Batsis, Ioannis
    Sotiropoulos, Damianos
    Anagnostopoulos, Achilles
    BONE MARROW TRANSPLANTATION, 2019, 54 (06) : 921 - 923
  • [6] BEAC (carmustine, etoposide, cytarabine, and cyclophosphamide) in autologous hematopoietic cell transplantation: a safe and effective alternative conditioning regimen for Hodgkin and non-Hodgkin lymphoma
    Ioanna Sakellari
    Eleni Gavriilaki
    Stella Bouziana
    Varnavas Constantinou
    Despina Mallouri
    Anna Vardi
    Anastasia Marvaki
    Ioannis Batsis
    Damianos Sotiropoulos
    Achilles Anagnostopoulos
    Bone Marrow Transplantation, 2019, 54 : 921 - 923
  • [7] TECAM (THIOTEPA, ETOPOSIDE, CYCLOPHOSPHAMIDE, ARA-C AND MELPHALAN) AS CONDITONING REGIMEN FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN AND HODGKIN LYMPHOMA
    Patir, P.
    Duran, M.
    Koseoglu, F.
    Uysal, A.
    Sahin, F.
    Tobu, M.
    Saydam, G.
    Vural, F.
    LEUKEMIA RESEARCH, 2016, 49 : S37 - S38
  • [8] A phase I and pharmacokinetic study of paclitaxel incorporated into the "augmented" high-dose cyclophosphamide, carmustine and etoposide (CBV) as conditioning chemotherapy for autologous stem cell transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Gokmen, E
    Callander, N
    Alexander, J
    Morris, A
    Tsai, TW
    Rosen, DM
    Anderson, J
    Alsina, M
    Craig, F
    Holle, L
    Cruz, J
    Baltathakis, I
    Hilsenbeck, S
    Valley, A
    West, L
    Egorin, MJ
    Freytes, CO
    BLOOD, 1999, 94 (10) : 320B - 320B
  • [9] Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV)
    Wheeler, C
    Khurshid, A
    Ibrahim, J
    Elias, A
    Mauch, P
    Ault, K
    Antin, J
    LEUKEMIA & LYMPHOMA, 2001, 40 (5-6) : 499 - 509
  • [10] Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin’s and non-Hodgkin’s B-cell lymphoma
    E Joffe
    D Rosenberg
    U Rozovski
    C Perry
    I Kirgner
    S Trestman
    O Gur
    F Aviv
    N Sarid
    A Kolomansky
    L Gepstein
    Y Herishanu
    E Naparstek
    Bone Marrow Transplantation, 2018, 53 : 29 - 33
12345